The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging

The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging - A Retrospective Cross-sectional Study Into Off-label Use of LDN

This retrospective, observational study will assess the health status of short- and long-term low-dose naltrexone (LDN) users.

Long-term (>5 years), intermediate-term (1-5 years), and short-term low-dose naltrexone (LDN) users (<12 months) will be contacted for a retrospective, observational assessment of their health status. Participants will be asked to complete a series of questionnaires assessing their quality of life, general physical and mental health, family history, the occurrence of age-related diseases, and immune status. Additionally, blood tests for immune and longevity markers will be optional for a subset of participants.

Inclusion Criteria:

• Adults (aged 18-120)
• Any sex
• Any ethnicity
• Taking LDN
• Willing to complete health questionnaires
• Technologically competent to complete web forms
• Subgroup: willing to undergo blood testing

Exclusion Criteria:

• LDN doses over 20 mg/day
• Terminal cancer patients (defined as stage IV and/or with a life expectancy of 12 months or less)